{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'Pl: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '3. Patient Population and Selection', 'Up to 33 patients will be enrolled at University of Washington Medical Center, in a 2-stage', 'design. The target population will be men with very low-risk to low-intermediate risk prostate', \"cancer (see 'risk' definitions under Inclusion Criteria) enrolled (or planning to enroll) on\", 'active surveillance.', '3.1. Inclusion Criteria', '1. Have signed an informed consent document', '2. Be willing/able to adhere to the prohibitions and restrictions specified in this', 'protocol', '3. Written Authorization for Use and Release of Health and Research Study', 'Information has been obtained', '4. Male aged 18 to 75 years or life expectancy >10 years (as determined by the', 'treating physician)', '5. Eastern cooperative group (ECOG) performance status 1', '6. Histologically confirmed adenocarcinoma of the prostate as documented by a', 'minimum 12 core prostate biopsy completed within 1-year of enrollment (Note:', 'most recent prostate biopsy must have demonstrated prostatic', 'adenocarcinoma)', '7.', 'Favorable risk prostate cancer as defined by:', 'Very low-risk', 'a. Clinical stage T1c disease', 'b. PSA density (PSAD) <0.15 ng/mL', 'C. Gleason score 6', 'd. 2 core biopsies with <50% involvement of any biopsy core with', 'cancer, or unilateral disease 2 core biopsies with any', 'percentage involvement', 'or', 'Low risk', 'a. Clinical stage T2a', 'b. PSA < 15 ng/mL', 'C. Gleason score 6', 'or', '27', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Low-intermediate risk', 'a. Clinical stage T1c', 'b. PSA <15ng/ml', 'C. Gleason 3+4 present in <50% of one core/site as detected by', 'systematic biopsy or MRI/TRUS fusion guided biopsy', 'd. Gleason 6 disease in all other cores/sites', '8. Willing and qualified for active surveillance at the University of Washington', '9. Serum testosterone >150 ng/dL', '10. Able to swallow the study drugs whole as a tablet', '11. Clinical laboratory values at screening:', 'a.', 'Hemoglobin >9.0 g/dL, independent of transfusion and/or growth', 'factors within 3 months prior to registration', 'b. Platelet count >100,000 X 109/L independent of transfusion', 'and/or growth factors within 3 months prior to registration', 'C. Serum albumin >3.0 g/dL', 'd. GFR >45 mL/min', 'e. Serum potassium >3.5 mmol/L', 'f.', \"Serum total bilirubin <1.5 x ULN (Note: In subjects with Gilbert's\", 'syndrome, if total bilirubin is >1.5 x ULN, measure direct and', 'indirect bilirubin and if direct bilirubin is <1.5 x ULN, subject may', 'be eligible)', 'g. Aspartate aminotransferase (AST) or alanine aminotransferase', '(ALT) <2.5 x ULN', '12. Medications known to lower the seizure threshold (see list under prohibited', 'meds) must be discontinued or substituted at least 4 weeks prior to study entry.', '13. Agrees to use a condom (even men with vasectomies) and another effective', 'method of birth control if he is having sex with a woman of childbearing potential', 'or agrees to use a condom if he is having sex with a woman who is pregnant', 'while on study drug and for 3 months following the last dose of study drug. Must', 'also agree not to donate sperm during the study and for 3 months after receiving', 'the last dose of study drug.', '3.2. Exclusion Criteria:', '28', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation', 'therapy, brachytherapy)', '2. Prior use of ARN-509 (apalutamide)', '3. Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide)', 'or its excipients', '4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:', 'a.', 'Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)', 'b. CYP-17 inhibitors (e.g., abiraterone, ketoconazole)', 'C. Antiandrogens (e.g., bicalutamide, nilutamide)', 'd. Second generation antiandrogens (e.g., enzalutamide)', 'e. Immunotherapy (e.g., sipuleucel-T, ipilimumab)', 'f.', 'Chemotherapy (e.g., docetaxel, cabazitaxel)', '5. Have any condition that, in the opinion of the investigator, would compromise the', 'well-being of the subject or the study or prevent the subject from meeting or', 'performing study requirements', '6. History of any of the following:', 'a. Seizure or known condition that may pre-dispose to seizure', '(including but not limited to prior stroke, transient ischemic attack,', 'loss of consciousness within 1 year prior to registration, brain', 'arteriovenous malformation; or intracranial masses such as', 'schwannomas and meningiomas that are causing edema or mass', 'effect)', 'b. Severe or unstable angina, myocardial infarction, symptomatic', 'congestive heart failure, arterial or venous thromboembolic events', '(e.g., pulmonary embolism, cerebrovascular accident including', 'transient ischemic attacks), or clinically significant ventricular', 'arrhythmias within 6 months prior to registration.', '29', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}